News

Our Weekly News digest clarifies and condenses the key developments and talking points in life sciences R&D. We identify and summarise the five top stories in quick-read format, so you have a full, clear and balanced picture of the latest advancements spanning diverse therapeutic areas and key development phases.
Designing the Future: AI Meets Antibody Engineering
Proteins, Antibodies & ADCs

Designing the Future: AI Meets Antibody Engineering

Lung-Targeted Delivery System for Gene Therapies Treats Cancer and Cystic Fibrosis
Cell & Gene

Lung-Targeted Delivery System for Gene Therapies Treats Cancer and Cystic Fibrosis

UCB Plans $5 Billion Manufacturing Investment to Boost Biologics Capacity
Proteins, Antibodies & ADCs

UCB Plans $5 Billion Manufacturing Investment to Boost Biologics Capacity

Landmark Study Links Newborn Gut Microbiome to Childhood Respiratory Health

Landmark Study Links Newborn Gut Microbiome to Childhood Respiratory Health

AstraZeneca Signs $5.3bn Deal for AI-Driven Research in China
Proteins, Antibodies & ADCs

AstraZeneca Signs $5.3bn Deal for AI-Driven Research in China

MIT and Recursion Go Public With Their AI model, Boltz-2, to Boost Drug Discovery
Proteins, Antibodies & ADCs

MIT and Recursion Go Public With Their AI model, Boltz-2, to Boost Drug Discovery

Adding IL-12 to mRNA Vaccines Enhances T Cell Response to Infection, Study Finds
Vaccines

Adding IL-12 to mRNA Vaccines Enhances T Cell Response to Infection, Study Finds

AZ Reduce Early-Stage Gastric Cancer Progression, Recurrence, and Death in Phase III Trial
Proteins, Antibodies & ADCs

AZ Reduce Early-Stage Gastric Cancer Progression, Recurrence, and Death in Phase III Trial

Preclinical Research Targets Newborn Stem Cells for In Vivo Gene Therapy
Cell & Gene

Preclinical Research Targets Newborn Stem Cells for In Vivo Gene Therapy

Positive Results for Kite’s CAR-T, Yescarta in R/R LBCL Outpatients
Cell & Gene

Positive Results for Kite’s CAR-T, Yescarta in R/R LBCL Outpatients

Infant Given Personalised Gene Therapy for Rare, Incurable Disease
Cell & Gene

Infant Given Personalised Gene Therapy for Rare, Incurable Disease

HAYA Therapeutics Raises $65M for its Dark Genome Therapy
Oligonucleotides

HAYA Therapeutics Raises $65M for its Dark Genome Therapy

Novo Nordisk CEO Lars Fruergaard Jørgensen Steps Down After Eight Years of Leadership
Peptides

Novo Nordisk CEO Lars Fruergaard Jørgensen Steps Down After Eight Years of Leadership

Brain Mapping Technology Uncovers Neural Pathways in Extraordinary Detail

Brain Mapping Technology Uncovers Neural Pathways in Extraordinary Detail

Moderna’s New GMP Vaccine Plant Now Operational
Vaccines

Moderna’s New GMP Vaccine Plant Now Operational

FDA Approves First-Ever Therapy for Rare Type of Ovarian Cancer

FDA Approves First-Ever Therapy for Rare Type of Ovarian Cancer

WHO Backs GLP-1 Agonists, will Discuss Essential Medicines List
Peptides

WHO Backs GLP-1 Agonists, will Discuss Essential Medicines List

Gene-Edited Tumour-Infiltrating Lymphocytes Show Clinical Promise Against Advanced Colorectal Cancers
Cell & Gene

Gene-Edited Tumour-Infiltrating Lymphocytes Show Clinical Promise Against Advanced Colorectal Cancers

IMAAVY Receives Seal of Approval from the FDA as First-in-Class Treatment for Generalised Myasthenia Gravis (gMG)
Proteins, Antibodies & ADCs

IMAAVY Receives Seal of Approval from the FDA as First-in-Class Treatment for Generalised Myasthenia Gravis (gMG)

Reeves, Trump, and the ‘Tariff Wall’: Can a Trade Deal Provide for UK Pharma?
Proteins, Antibodies & ADCs

Reeves, Trump, and the ‘Tariff Wall’: Can a Trade Deal Provide for UK Pharma?

Time is of the Essence: Why 2025 is a Unique Opportunity for APAC Biotech
Proteins, Antibodies & ADCs

Time is of the Essence: Why 2025 is a Unique Opportunity for APAC Biotech

NICE Gives Green Light to AstraZeneca’s Advanced Breast Cancer Drug, Capivasertib
Proteins, Antibodies & ADCs

NICE Gives Green Light to AstraZeneca’s Advanced Breast Cancer Drug, Capivasertib

You're just a click away

To access our site, please accept the Terms of Use - our full terms of use are available below.
Full Terms of Use

By rejecting you won't be able to progress to the LifeScienceXchange platform.